Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Why has Health Yuan's 'Shutanlin' become a milestone in domestic respiratory disease inhalation preparations?
Published Time：
2020-02-20
In China, multinational pharmaceutical giants have long held over 90% of the market for inhalation preparations related to respiratory diseases. This market has always been called the "highest-end and most difficult segment in the generic drug field."
On April 9 this year, HealthGen's "Shutanlin" (ipratropium bromide and salbutamol inhalation solution) was approved for marketing. The launch of "Shutanlin" has milestone significance for the R&D of domestic generic inhalation preparations, and its appearance will open a new chapter in the domestic inhalation preparation market. The reason is that "Shutanlin" is the first drug to pass the consistency evaluation among all respiratory disease-related inhalation preparations, and the first new Class 4 registered nebulized inhalation solution in China.
So, what are the reasons for the successful R&D and launch of "Shutanlin"?
Strong capital is an important driving force for R&D
Founded on December 18, 1992, and listed on the Shanghai Stock Exchange in June 2001, HealthGen, which is committed to becoming a leader in China's big health industry, consists of Lizhu Pharmaceutical and HealthGen Pharmaceutical. Its business involves more than 500 varieties in multiple fields, including chemical preparations, raw materials, diagnostic reagents, monoclonal antibodies, and health products. It is a comprehensive group company integrating R&D, production, sales, and services of pharmaceuticals and health products. By the end of 2018, the company's total assets reached RMB 24.986 billion, and it was selected as Top 10 in the "2018 China Chemical Pharmaceutical Enterprise TOP 100 Ranking"! Starting in 2013, HealthGen has conducted in-depth research on respiratory drugs and invested a large amount of funds in R&D, with cumulative R&D investment exceeding 100 million yuan.
Excellent scientific research configuration is a strong backing for R&D
Also in 2013, HealthGen Group joined forces with a top domestic R&D team led by Professor Jin Fang, a leading figure in China's respiratory preparation research and current professional committee member of the Chinese Pharmacopoeia Commission, to jointly establish Shanghai Fangyu Health Pharmaceutical Technology Co., Ltd., forming a research service platform for respiratory system drugs with first-class technical level in China. In 2015, a joint venture was established with the Guangzhou Institute of Respiratory Diseases led by Academician Zhong Nanshan to establish Guangzhou HealthGen Respiratory Drug Engineering Technology Co., Ltd., dedicated to the R&D of inhalation preparations. Currently, HealthGen Group has more than 20 inhalation preparation products under research.
On one side is a powerful comprehensive pharmaceutical group, and on the other side is a domestic R&D team that masters high-end technical thresholds. This story of the collision between technology and capital begins with "Shutanlin".
As a milestone drug for inhalation preparations, the launch of "Shutanlin" has broken the long-standing technological monopoly of original research products in China. At the same time, as a compound preparation, each bottle of "Shutanlin" nebulized solution contains 2.5mg of salbutamol and 0.5mg of ipratropium bromide. The golden ratio of 5:1 provides patients with chronic obstructive pulmonary disease and asthma and other airway obstructive diseases with a more convenient and safer medication option.
It is believed that after "Shutanlin", HealthGen Group will become increasingly stable in the innovation and R&D of inhalation preparations. The series of upcoming inhalation preparation products are even more anticipated!
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.